Par Pharma Begins Shipping Generic Atacand HCT

By: Benzinga
Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca (NYSE: AZN ) to distribute the authorized generic version of AstraZeneca's Atacand HCT^® (candesartan cilexetil/hydrochlorothiazide). Par has begun shipping 16/12.5 mg, 32/12.5 mg and 32/25 mg strengths of candesartan cilexetil/
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.